{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T02:06:56Z","timestamp":1780711616358,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"DOI":"10.1007\/s10822-026-00840-3","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:51:26Z","timestamp":1780710686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of potent and selective LRRK2 inhibitors with preserved activity against the G2019S mutant via multi-stage virtual screening"],"prefix":"10.1007","volume":"40","author":[{"given":"Yan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinle","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roufen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongkuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"840_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/jpd-181374","volume":"8","author":"SKL Darweesh","year":"2018","unstructured":"Darweesh SKL et al (2018) Parkinson Matters. J Parkinsons Dis 8:495\u2013498. https:\/\/doi.org\/10.3233\/jpd-181374","journal-title":"J Parkinsons Dis"},{"key":"840_CR2","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","volume":"132","author":"MT Hayes","year":"2019","unstructured":"Hayes MT (2019) Parkinson\u2019s Disease and Parkinsonism. Am J Med 132:802\u2013807. https:\/\/doi.org\/10.1016\/j.amjmed.2019.03.001","journal-title":"Am J Med"},{"key":"840_CR3","doi-asserted-by":"crossref","unstructured":"Kouli A, Torsney KM, Kuan W-L (2018) Parkinson\u2019s disease: etiology, neuropathology, and pathogenesis. Exon Publications, 3\u201326","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"840_CR4","doi-asserted-by":"publisher","unstructured":"Kalia LV, Lang AE (2015) Parkinson's disease. Lancet 386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","DOI":"10.1016\/S0140-6736(14)61393-3"},{"key":"840_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/toxsci\/kfad086","volume":"196","author":"SL Boyd","year":"2023","unstructured":"Boyd SL et al (2023) Developmental exposure to the Parkinson\u2019s disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in \u03b1-synuclein pre-formed fibril (PFF)-injected mice. Toxicol Sci 196:99\u2013111. https:\/\/doi.org\/10.1093\/toxsci\/kfad086","journal-title":"Toxicol Sci"},{"key":"840_CR6","unstructured":"Sonne J, Reddy V, Beato MR, Neuroanatomy (2024) substantia nigra. StatPearls [Internet]. StatPearls Publishing"},{"key":"840_CR7","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/s0140-6736(21)00218-x","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303. https:\/\/doi.org\/10.1016\/s0140-6736(21)00218-x","journal-title":"Lancet"},{"key":"840_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/s0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912. https:\/\/doi.org\/10.1016\/s0140-6736(14)61393-3","journal-title":"Lancet"},{"key":"840_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","volume":"11","author":"A AlDakheel","year":"2014","unstructured":"AlDakheel A, Kalia LV, Lang AE (2014) Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 11:6\u201323","journal-title":"Neurotherapeutics"},{"key":"840_CR10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00702-018-1900-6","volume":"125","author":"TN Tran","year":"2018","unstructured":"Tran TN, Vo TN, Frei K, Truong DD (2018) Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm 125:1109\u20131117","journal-title":"J Neural Transm"},{"key":"840_CR11","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1021\/acs.jmedchem.2c01552","volume":"66","author":"X Tang","year":"2023","unstructured":"Tang X et al (2023) The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson\u2019s Disease. J Med Chem 66:2282\u20132307. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01552","journal-title":"J Med Chem"},{"key":"840_CR12","doi-asserted-by":"publisher","unstructured":"Steger M, Tonelli F, Ito G, Davies P, Trost M, Vetter M, Mann M (2016) Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5:e12813. https:\/\/doi.org\/10.7554\/eLife.12813","DOI":"10.7554\/eLife.12813"},{"key":"840_CR13","doi-asserted-by":"publisher","first-page":"e100875","DOI":"10.15252\/embj.2018100875","volume":"39","author":"T Toyofuku","year":"2020","unstructured":"Toyofuku T, Okamoto Y, Ishikawa T, Sasawatari S, Kumanogoh A (2020) LRRK2 regulates endoplasmic reticulum-mitochondrial tethering through the PERK-mediated ubiquitination pathway. Embo j 39:e100875. https:\/\/doi.org\/10.15252\/embj.2018100875","journal-title":"Embo j"},{"key":"840_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","volume":"588","author":"CK Deniston","year":"2020","unstructured":"Deniston CK et al (2020) Structure of LRRK2 in Parkinson\u2019s disease and model for microtubule interaction. Nature 588:344\u2013349. https:\/\/doi.org\/10.1038\/s41586-020-2673-2","journal-title":"Nature"},{"key":"840_CR15","doi-asserted-by":"publisher","unstructured":"Liu TW, Chen CM, Chang KH (2022) Biomarker of Neuroinflammation in Parkinson\u2019s Disease. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms23084148","DOI":"10.3390\/ijms23084148"},{"key":"840_CR16","doi-asserted-by":"publisher","unstructured":"Taymans JM et al (2023) Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis 9. https:\/\/doi.org\/10.1038\/s41531-023-00544-7","DOI":"10.1038\/s41531-023-00544-7"},{"key":"840_CR17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02473","author":"O Moukha-Chafiq","year":"2025","unstructured":"Moukha-Chafiq O et al (2025) Discovery of a Chiral 2,4-Substituted Pyrrolo [2,3-d]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02473","journal-title":"J Med Chem"},{"key":"840_CR18","doi-asserted-by":"publisher","first-page":"115475","DOI":"10.1016\/j.ejmech.2023.115475","volume":"256","author":"J Hu","year":"2023","unstructured":"Hu J et al (2023) Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives. Eur J Med Chem 256:115475. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115475","journal-title":"Eur J Med Chem"},{"key":"840_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings D et al (2023) LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson\u2019s Disease. Mov Disord 38:386\u2013398. https:\/\/doi.org\/10.1002\/mds.29297","journal-title":"Mov Disord"},{"key":"840_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/acn3.51776","volume":"10","author":"YL Sosero","year":"2023","unstructured":"Sosero YL, Gan-Or Z (2023) LRRK2 and Parkinson\u2019s disease: from genetics to targeted therapy. Ann Clin Transl Neurol 10:850\u2013864. https:\/\/doi.org\/10.1002\/acn3.51776","journal-title":"Ann Clin Transl Neurol"},{"key":"840_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/s1474-4422(21)00061-2","volume":"20","author":"N Vijiaratnam","year":"2021","unstructured":"Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T (2021) Progress towards therapies for disease modification in Parkinson\u2019s disease. Lancet Neurol 20:559\u2013572. https:\/\/doi.org\/10.1016\/s1474-4422(21)00061-2","journal-title":"Lancet Neurol"},{"key":"840_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s1474-4422(21)00330-6","volume":"21","author":"D Weintraub","year":"2022","unstructured":"Weintraub D et al (2022) The neuropsychiatry of Parkinson\u2019s disease: advances and challenges. Lancet Neurol 21:89\u2013102. https:\/\/doi.org\/10.1016\/s1474-4422(21)00330-6","journal-title":"Lancet Neurol"},{"key":"840_CR23","doi-asserted-by":"publisher","first-page":"14821","DOI":"10.1021\/acs.jmedchem.0c01243","volume":"63","author":"AW Garofalo","year":"2020","unstructured":"Garofalo AW et al (2020) Selective Inhibitors of G2019S-LRRK2 Kinase Activity. J Med Chem 63:14821\u201314839. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01243","journal-title":"J Med Chem"},{"key":"840_CR24","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1021\/acschemneuro.4c00657","volume":"15","author":"S Tan","year":"2024","unstructured":"Tan S, Liu H, Yao X (2024) LRRK2 Inhibitors as Promising Treatment for Parkinson\u2019s Disease. ACS Chem Neurosci 15:4092\u20134094. https:\/\/doi.org\/10.1021\/acschemneuro.4c00657","journal-title":"ACS Chem Neurosci"},{"key":"840_CR25","doi-asserted-by":"publisher","unstructured":"Zhu H, Zhang Y, Li W, Huang NA (2022) Comprehensive Survey of Prospective Structure-Based Virtual Screening for Early Drug Discovery in the Past Fifteen Years. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms232415961","DOI":"10.3390\/ijms232415961"},{"key":"840_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41531-024-00826-8","volume":"10","author":"MB William","year":"2024","unstructured":"William MB et al (2024) The p.Gly2019Ser is a common LRRK2 pathogenic variant among Egyptians with familial and sporadic Parkinson\u2019s disease. NPJ Parkinsons Dis 10:215. https:\/\/doi.org\/10.1038\/s41531-024-00826-8","journal-title":"NPJ Parkinsons Dis"},{"key":"840_CR27","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.3390\/ijms22094435","volume":"22","author":"TB Kimber","year":"2021","unstructured":"Kimber TB, Chen Y, Volkamer A (2021) Deep Learning in Virtual Screening: Recent Applications and Developments. Int J Mol Sci 22:4435","journal-title":"Int J Mol Sci"},{"key":"840_CR28","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1021\/acscentsci.8b00717","volume":"4","author":"M Aldeghi","year":"2018","unstructured":"Aldeghi M, Gapsys V, de Groot BL (2018) Accurate Estimation of Ligand Binding Affinity Changes upon Protein Mutation. ACS Cent Sci 4:1708\u20131718. https:\/\/doi.org\/10.1021\/acscentsci.8b00717","journal-title":"ACS Cent Sci"},{"key":"840_CR29","doi-asserted-by":"publisher","unstructured":"Meli R, Morris GM, Biggin PC (2022) Scoring Functions for Protein-Ligand Binding Affinity Prediction Using Structure-based Deep Learning: A Review. Front Bioinf 2\u20132022. https:\/\/doi.org\/10.3389\/fbinf.2022.885983","DOI":"10.3389\/fbinf.2022.885983"},{"key":"840_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41531-025-00870-y","volume":"11","author":"L Dou","year":"2025","unstructured":"Dou L et al (2025) A network-based systems genetics framework identifies pathobiology and drug repurposing in Parkinson\u2019s disease. npj Parkinson\u2019s Disease 11:22. https:\/\/doi.org\/10.1038\/s41531-025-00870-y","journal-title":"npj Parkinson\u2019s Disease"},{"key":"840_CR31","doi-asserted-by":"publisher","unstructured":"Bento AP et al (2020) An open source chemical structure curation pipeline using RDKit. J Cheminform 12. https:\/\/doi.org\/10.1186\/s13321-020-00456-1","DOI":"10.1186\/s13321-020-00456-1"},{"key":"840_CR32","unstructured":"Schr\u00f6dinger (2021) Release 2021-2: LigPrep, Schr\u00f6dinger, LLC, New York"},{"key":"840_CR33","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","volume":"17","author":"C Lu","year":"2021","unstructured":"Lu C et al (2021) OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. J Chem Theory Comput 17:4291\u20134300. https:\/\/doi.org\/10.1021\/acs.jctc.1c00302","journal-title":"J Chem Theory Comput"},{"key":"840_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","volume":"21","author":"JC Shelley","year":"2007","unstructured":"Shelley JC et al (2007) Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21:681\u2013691. https:\/\/doi.org\/10.1007\/s10822-007-9133-z","journal-title":"J Comput Aided Mol Des"},{"key":"840_CR35","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1021\/acs.jctc.6b00805","volume":"12","author":"AD Bochevarov","year":"2016","unstructured":"Bochevarov AD, Watson MA, Greenwood JR, Philipp DM, Multiconformation (2016) Density Functional Theory-Based pK(a) Prediction in Application to Large, Flexible Organic Molecules with Diverse Functional Groups. J Chem Theory Comput 12:6001\u20136019. https:\/\/doi.org\/10.1021\/acs.jctc.6b00805","journal-title":"J Chem Theory Comput"},{"key":"840_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/pro.3730","volume":"29","author":"DS Goodsell","year":"2020","unstructured":"Goodsell DS et al (2020) RCSB Protein Data Bank: Enabling biomedical research and drug discovery. Protein Sci 29:52\u201365. https:\/\/doi.org\/10.1002\/pro.3730","journal-title":"Protein Sci"},{"key":"840_CR37","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/jp003020w","volume":"105","author":"P Mark","year":"2001","unstructured":"Mark P, Nilsson L (2001) Structure and Dynamics of the TIP3P, SPC, and SPC\/E Water Models at 298 K. J Phys Chem A 105:9954\u20139960","journal-title":"J Phys Chem A"},{"key":"840_CR38","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1021\/ct400314y","volume":"9","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer R, G\u00f6tz AW, Poole D, Le Grand S, Walker RC (2013) Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. J Chem Theory Comput 9:3878\u20133888. https:\/\/doi.org\/10.1021\/ct400314y","journal-title":"J Chem Theory Comput"},{"key":"840_CR39","doi-asserted-by":"publisher","first-page":"eadk6191","DOI":"10.1126\/sciadv.adk6191","volume":"9","author":"M Sanz Murillo","year":"2023","unstructured":"Sanz Murillo M et al (2023) Inhibition of Parkinson\u2019s disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Sci Adv 9:eadk6191. https:\/\/doi.org\/10.1126\/sciadv.adk6191","journal-title":"Sci Adv"},{"key":"840_CR40","doi-asserted-by":"publisher","unstructured":"Villagran-Suarez A, Sanz-Murillo M, Alegrio-Louro J, Leschziner A (2023) Structure of C-terminal half of LRRK2 bound to GZD-824. https:\/\/doi.org\/10.2210\/pdb8tze\/pdb","DOI":"10.2210\/pdb8tze\/pdb"},{"key":"840_CR41","doi-asserted-by":"publisher","unstructured":"Sanz-Murillo M, Villagran-Suarez A, Alegrio-Louro J, Leschziner A (2023) Structure of C-terminal LRRK2 bound to MLi-2 (G2019S mutant). https:\/\/doi.org\/10.2210\/pdb8tzc\/pdb","DOI":"10.2210\/pdb8tzc\/pdb"},{"key":"840_CR42","unstructured":"Zhou G et al in International Conference on Learning Representations."},{"key":"840_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s42256-021-00409-9","volume":"3","author":"O M\u00e9ndez-Lucio","year":"2021","unstructured":"M\u00e9ndez-Lucio O, Ahmad M, del Rio-Chanona EA, Wegner JK (2021) A geometric deep learning approach to predict binding conformations of bioactive molecules. Nat Mach Intell 3:1033\u20131039. https:\/\/doi.org\/10.1038\/s42256-021-00409-9","journal-title":"Nat Mach Intell"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10822-026-00840-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-026-00840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:51:29Z","timestamp":1780710689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10822-026-00840-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s10822-026-00840-3","relation":{},"ISSN":["1573-4951"],"issn-type":[{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}